info@cymabay.com
(917) 877-2194
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
24
Jul
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
19
Jul
CymaBay Announces Pricing of Public Offering of Common Stock
17
Jul
CymaBay Announces Proposed Public Offering of Common Stock
17
Jul
CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis
26
Jun
CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance
11
May
CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update
4
May
CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11
13
Apr
CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017
30
Mar
CymaBay Therapeutics to Present at Two Investor Conferences in April
29
Mar
CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.
<< Previous
1...
2
3
4
5
6
7
8
9
10
11
...17
Next >>
Show All
Scroll
